the Effect of Opioid-free General Anesthesia
the Effect of Opioid-free General Anesthesia on the Recovery Quality After Gynecological Laparoscopy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Seocho-gu
-
Seoul, Seocho-gu, Korea, Republic of, 07651
- Seoul St.Mary's Hospital
-
Seoul, Seocho-gu, Korea, Republic of, 06591
- Seoul St.Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient scheduled for gynecological laparoscopic surgery
Exclusion Criteria:
- refusal to participate in this study
- emergent surgery
- chronic pain requiring for pain killer
- psychiatric disease
- preoperative bradycardia or hypotension
- allergy or history of the adverse effect to study drug
- pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: opioid-free anesthesia
The study group receives the dexmedetomidine and lidocaine infusion with general anesthesia for gynecological laparoscopy.
|
dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
Other Names:
lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
Other Names:
|
|
ACTIVE_COMPARATOR: opioid anesthesia
The control group receives the remifentanil infusion with general anesthesia for gynecological laparoscopy.
|
remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the quality of recovery
Time Frame: at 24 hour after the completion of surgery
|
The quality of recovery is assessed using questionnaire.
This questionnaire includes 40 items.
The score range is from 40 to 200.
The higher score means the better quality of recovery after surgery.
|
at 24 hour after the completion of surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cytokine
Time Frame: during surgery
|
as ancillary study, to assess the various kinds of cytokines such as epinephrine, norepinephrine, interleukin-10, tumor necrosis factor-alpha.
|
during surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Youngeun Moon, MD, Seoul St. Mary'S Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Analgesics, Opioid
- Narcotics
- Membrane Transport Modulators
- Hypnotics and Sedatives
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Remifentanil
- Dexmedetomidine
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- OFGA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.